Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast Cancer

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investiga

Related Keywords

Miami ,Florida ,United States ,Ireland ,New York ,California ,American ,Michelle Rudek ,Avonne Oconnor ,Robert Anders ,Sarah Shin ,Chenguang Wang ,Roisin Connolly ,Johns Hopkins ,Evanthia Roussos Torres ,James Leatherman ,Qingfeng Zhu ,Los Angeles ,Alexei Hernandez ,Ludmila Danilova ,Roussos Torres ,Elizabeth Jaffee ,Christine Rafie ,Elana Fertig ,Elizabeth Engle ,Vered Stearns ,Joseph Tandurella ,University College Cork ,Cancer Therapy Evaluation Program ,Kimmel Cancer Center ,Ohio State University ,Parker Institute ,University Of Pittsburgh Cancer Institute ,University Of Pittsburgh Hillman Cancer Center ,Johns Hopkins University School Of Medicine ,Genentech ,Johns Hopkins University ,National Cancer Institute ,Home Group ,Yale Cancer Center ,University Of Miami Miller School Medicine ,Johns Hopkins Kimmel Cancer Center ,Johns Hopkins Kimmel Cancer ,Nature Cancer ,Southern California Keck School ,Johns Hopkins University School ,Weill Cornell Medicine ,Melinda Downs ,Avonneo Connor ,Miami Miller School ,Pittsburgh Cancer Institute ,Hillman Cancer Center ,Cedars Sinai Cancer ,Ohio State ,Medical Home Group ,Break Through Cancer ,Newswise ,Lizabeth Jaffee Johns Hopkins Kimmel Cancer Center Breast Advanced Her 2 ,All Journal News ,Johns Hopkins Medicine ,